immatics biotechnologies GmbH

Biotechnology

  • Short facts

    • Manufacturer
  • Year founded not available
  • Employees (site): not available
  • Turnover: not available

Products/services: immatics has a good track record of success: We are optimistic that we have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severe side effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. We are currently working on the development of new substances for a number of specific cancer types. Our most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. immatics has a good track record of success: We are optimistic that we have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severe side effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. We are currently working on the development of… read more 

Basic data

Company

immatics biotechnologies GmbH

Street

Machtfliegerstr. 11

PC / City

81379 München

County

Upper Bavaria

Phone

+49 89 540415-0

Fax

+49 89 540415-905

Language skills

English

Profile/competences

Core competencies

not available

Key sectors / sub-sectors

  • Biotechnology: Therapeutic drug development

Certifications

not available

Sales markets - target industries

not available

Sales markets - target countries

not available

Cooperation offers

not available